CMMB – chemomab therapeutics ltd. - american depositary shares (US:NASDAQ)
Stock Stats
News
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $11.00 price target on the stock, down previously from $13.00.
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
Form 424B5 Chemomab Therapeutics
Form 6-K Chemomab Therapeutics For: Nov 14
Form 6-K Chemomab Therapeutics For: Oct 11
Form SC 13D/A Chemomab Therapeutics Filed by: OrbiMed Israel BioFund GP Limited Partnership
Form 144 Chemomab Therapeutics Filed by: OrbiMed Israel GP Ltd.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.